Key Takeaways
- Volume-led 39% revenue surge, but price/mix drag persists: Agrochemical volumes jumped 48% YoY while non-agro volumes more than doubled, yet negative price and product mix of -24% in Q4 signals the competitive intensity that forced margin sacrifice for market share.
- Gross margin recovery underway, not complete: FY25 gross margin expanded 400 bps to 29.9%, but Q4 slipped to 29.8% from 34.6% a year ago as the company prioritized volume and share over price. Management expects further improvement in FY26 as raw material prices stabilize and prices increase.
- Working capital turned a corner: A 40-day reduction in the working capital cycle to 118 days, driven by aggressive receivables recovery, strengthens the balance sheet after a year of heavy investment in registrations and capex.
- The China overcapacity cycle is maturing: Management declared the dumping story over, with many products trading at 25% of prior-year prices, a level it calls abnormal and expects to normalize through price increases of 10-15% in FY26.
- What to watch next quarter: Whether the promised 10-15% price increase materializes from Q1, whether agrochem EBIT margins begin their promised revival from the 12% trough, and whether the US tariff pass-through mechanism holds as customers continue to "gracefully accept" higher costs.
Volume Growth & Market Share Strategy
- Volume over price was the deliberate Q4 trade: Agrochemical volumes grew 48% YoY and non-agrochemical volumes grew 116% YoY, but this came with a negative price and product mix of -24% for the quarter as the company offered attractive prices to capture market share in a still-oversupplied environment.
- Europe led the charge: Strong volume and value growth in Europe was driven by proactive customer engagement, understanding estimated product requirements 2-3 months in advance and ensuring timely availability when competitors could not deliver.
- Latin America and NAFTA contributed meaningfully: Both regions were key contributors to agrochemical segment growth, though the US tariff situation introduces a new variable for NAFTA going forward.
- Non-agro realization dropped sharply: Volume growth of 116% translated to only 42% value growth in Q4, which management attributed to normal variations and some increase in cost per unit, while explicitly denying any pre-buying ahead of tariffs.
- The global market share runway is large: The company holds only 4-5% of the global market; adding 1 percentage point of share would mean a 20-25% revenue increase, a target management considers achievable given the fragmentation of the industry.
- Herbicides remain a growth vector: Herbicides will continue to grow, with better margins on new products where the company is the second or third registration holder, depending on product mix.
Bubna: "Whenever you want to have market share, it has to be, you have to sacrifice some margins. It is unwritten law. If you want to prepare for margins, then we have to sacrifice the market share."
Pricing & Margin Dynamics
- The price trough is abnormal and should reverse: Many products are trading at 25% of previous years' prices due to excess Chinese production in 2024 and H2 2023, a level management calls unsustainable and expects to normalize with price increases of 10-15% in FY26.
- Gross margin improvement is the FY26 expansion driver: FY25 gross margin recovered to 29.9% from 25.9% in FY24, a 400 bps improvement, and management expects further expansion in FY26 as raw material prices stabilize and selling prices increase, with Q4's 29.8% level as a floor with upside.
- Agrochem EBIT margins are at a trough: Q4 agrochem segment EBIT margin fell to 12%, down from 16% in prior-year periods, with management promising revival "during the next year" without specifying a quarter or catalyst.
- Non-agrochem EBIT margins are normalizing upward: Margins in this segment are constantly increasing, with management considering 20-23% as the normal range going forward.
- No residual high-cost inventory overhang: The company carries no high-cost inventories that would delay margin recovery, and write-offs are negligible, perhaps 1 in 100 cases.
- Price and mix drag is bottoming: The negative price and product mix of -24% in Q4 and -12% for FY25 reflects a shift toward commoditized products with excess availability, but management expects this to improve by 10-15% in FY26.
Bubna: "Many of the products today are being traded at a price of 25% of what it was being traded in the previous years. So this low price is also very abnormal and it will come to normalcy, that would mean increase in the prices."
China, Tariffs & Competitive Landscape
- Chinese dumping cycle is over, but overcapacity remains: The dumping story ended 12-15 months ago, yet China continues to produce enough quantities to meet world requirements, keeping prices depressed. Management sees no trend of Chinese dumping shifting to other regions due to US tariffs.
- US tariff pass-through is working, for now: The company is able to pass tariff increases to customers, who are "gracefully accepting it," with the burden ultimately falling on the US consumer. Management expects the US President may correct himself further on tariff policy.
- US formulation strategy favors China sourcing: The cost of formulated product from China is higher due to duty differentials, but US formulating capacities are limited and expensive, and customers prefer timely delivery from China, sustaining the current sourcing pattern.
- Chinese companies struggle with registration complexity: Some Chinese companies are attempting registrations, but the process is highly capital-intensive, uncertain, and lengthy, discouraging many from making progress. Management is waiting to see if they can make an impact.
- Registration costs are rising: The registration process is becoming more expensive, with the company maintaining a budget of ₹200-400 cr, though the annual count of new registrations has declined from 130-140 to 45.
Bubna: "No, that Chinese dumping story is over about a year back. This was there about 12 to 15 months earlier. Now the dumping process is lower, but China is producing enough quantities to make the world requirement."
Financial Health & Capital Allocation
- EBITDA and PAT rebounded sharply in FY25: FY25 EBITDA grew 114% to ₹682 cr at a 15.8% margin, while PAT surged 854% to ₹304 cr, recovering from a depressed FY24 base. Q4 EBITDA grew 16% to ₹352 cr at a 19.2% margin.
- Working capital cycle improved materially: Working capital days fell by 40 days to 118 days, driven by extra efforts to recover receivables, with customers responding positively and no significant write-offs incurred.
- Capex remains elevated for registrations: FY25 capex stood at ₹420 cr, with FY26 guidance of ₹400-450 cr, reflecting the ongoing investment in building the registration portfolio, which now stands at 2,964 with 1,014 applications in process globally.
- Dividend signals confidence: The board recommended a final dividend of ₹6 per share, 60% of face value, following a year of strong profit recovery.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 10-15% top-line growth for both agro and non-agro segments | FY26 |
| EBITDA margin | Maintain 15-18% EBITDA margin | FY26 |
| Price increase | 10-15% increase in prices and product mix | FY26, some improvement visible from Q1 |
| Gross margin | Improvement from Q4's 29.8% level, driven by pricing and raw material stabilization | FY26 |
| Agrochem EBIT margin revival | Recovery from 12% Q4 trough toward prior 16% levels | "During the next year" |
| Capex | ₹400-450 cr | FY26 |
| Registration spend | ₹200-400 cr budget maintained | Ongoing |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹1,829 cr, +39% YoY |
| Agrochemical revenue | ₹1,691 cr, +39% YoY |
| Non-agrochemical revenue | ₹138 cr, +42% YoY |
| Overall volume growth | ~50% YoY |
| Agrochemical volume growth | 48% YoY |
| Non-agrochemical volume growth | 116% YoY |
| Gross margin | 29.8%, vs 34.6% in Q4 FY24 |
| EBITDA | ₹352 cr, +16% YoY |
| EBITDA margin | 19.2% |
| PAT | ₹204 cr, +42% YoY |
| FY26 revenue growth guidance | >15% |
| FY26 EBITDA margin guidance | 15% to 18% |
| Working capital days | 118 days, improved 40 days vs March 2024 |
| Cash and cash equivalents | ₹558 cr as of 31 March 2025 |
| Capex (FY25) | ₹420 cr |
| Capex guidance (FY26) | ₹400 cr to ₹450 cr |
| Total product registrations | 2,964 as of 31 March 2025 |
| Registration applications in process | 1,014 |
| ROCE | 16% as of March 2025 |
| ROE | 12.8% as of March 2025 |
| Final dividend | ₹6 per share, 60% of face value |
| Q4 volume growth (precise) | 49.8% |
| Q4 FX effect | +13% |
| Q4 price and product mix | -24% |
| FY25 full-year volume growth | 42% |
| FY25 full-year FX impact | +7% |
| FY25 full-year price and product mix | -12% |
| FY25 full-year agro volume growth by region: Europe | 58% |
| FY25 full-year agro volume growth by region: NAFTA | 36% |
| FY25 full-year agro volume growth by region: LatAm | 25% |
| FY25 full-year agro volume growth by region: Rest of World | -1.5% |
| Q4 agrochem gross margin by region: Europe | 34.2% |
| Q4 agrochem gross margin by region: NAFTA | 19.5% |
| Q4 agrochem gross margin by region: LatAm | 27% |
| Q4 agrochem gross margin by region: Rest of World | 40% |
| Non-agro sales in US market (FY25) | ~₹315 cr |
| Global market share | ~4% to 5% |